# Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEP

> **NCT05067166** · — · AVAILABLE · sponsor: **Ridgeback Biotherapeutics, LP**

## Conditions studied

- Ebola Virus Disease

## Interventions

- **DRUG:** Ansuvimab

## Key facts

- **NCT ID:** NCT05067166
- **Lead sponsor:** Ridgeback Biotherapeutics, LP
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2024-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05067166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05067166, "Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEP". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05067166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*